STELARA™ is a human IgG1k monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons. STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL.
STELARA™ is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Media Articles Related to Stelara (Ustekinumab)
NICE recommends Stelara (ustekinumab) for the treatment of active psoriatic arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2015.03.16]
Janssen has announced that the National Institute for Health and Clinical Excellence (NICE), has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD)1 as a treatment...
Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.03.25]
For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.
IL-17 Inhibitor Clears Psoriasis More Often
Source: MedPage Today Dermatology [2015.03.22]
(MedPage Today) -- Brodalumab twice as likely to clear all lesions as ustekinumab.
Biologics Take Aim at Psoriasis Despite Worry Over Reactions
Source: Medscape Dermatology Headlines [2015.03.26]
The oral drug tofacitinib, typically prescribed for rheumatoid arthritis, is showing promise for the treatment of psoriasis, and new experimental agents are gaining ground.
Medscape Medical News
Tough-to-Treat Psoriasis Responds to Anti-PDE4
Source: MedPage Today Allergy & Immunology [2015.03.25]
(MedPage Today) -- Response at 16 weeks maintained a full year in most cases.
Published Studies Related to Stelara (Ustekinumab)
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe
plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). 
moderate to severe plaque-type psoriasis... CONCLUSIONS: Consistent with results previously reported in global phase 3
An update on the long-term safety experience of ustekinumab: results from the
psoriasis clinical development program with up to four years of follow-up. 
severe psoriasis treated for up to four years... CONCLUSION: The safety profile of long-term ustekinumab treatment with up to four
Long-term safety experience of ustekinumab in patients with moderate to severe
psoriasis (Part II of II): results from analyses of infections and malignancy
from pooled phase II and III clinical trials. 
exposed up to 3 years... CONCLUSIONS: The emerging safety profile of ustekinumab remains favorable and
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. 
This phase 2/3, double-blind, placebo-controlled study was designed to assess the
safety and efficacy of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis. Overall, 158 patients were randomized to receive
ustekinumab 45 or 90 mg at weeks 0, 4, and every 12 weeks, or placebo with
cross-over to ustekinumab at week 12...
Long-term safety experience of ustekinumab in patients with moderate-to-severe
psoriasis (Part I of II): results from analyses of general safety parameters from
pooled Phase 2 and 3 clinical trials. 
ustekinumab through 3 years of treatment... CONCLUSIONS: The safety profile of continued ustekinumab exposure through up to 3
Clinical Trials Related to Stelara (Ustekinumab)
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis [Recruiting]
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of
ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis [Recruiting]
This study will provide data on sasety and efficacy of Ustekinumab in patients suffering
from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) [Recruiting]
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients
with moderate to severe psoriasis.
TRANSIT - A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate [Recruiting]
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who
receive ustekinumab following an inadequate response to methotrexate therapy. The study
will provide information for doctors on how to manage the transfer from methotrexate to the
biologic agent ustekinumab. The study is designed to compare two methods of transferring
patients from methotrexate to ustekinumab. The two methods being compared are
discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation
of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients
with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
Reports of Suspected Stelara (Ustekinumab) Side Effects
Myocardial Infarction (71),
Drug Ineffective (67),
OFF Label USE (41),
Drug Dose Omission (34),
Psoriatic Arthropathy (34), more >>